The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.

Motif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its ...

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

This content is provided by Almac Group, and any views and opinions expressed do not necessarily reflect those of www.outsourcing-pharma.com Related categories: Analytical testing, QC Solid phase ...